A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome or Acute Myelogenous Leukemia.

Trial Profile

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome or Acute Myelogenous Leukemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Mocetinostat (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 08 Nov 2013 Results will be presented at the 55th Annual Meeting of the American Society of Hematology in December 2013.
    • 03 Jun 2013 Data was presented at the 2013 ASCO Annual Meeting, according to a MethylGene media release.
    • 21 Nov 2009 Actual initiation date changed from 1 Jan 2006 to 2 Dec 2005 as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top